Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cabazitaxel in Platinum Refractory Ovarian Cancer

This study has been terminated.
(Too low inclusion rate. Only 4 patients included over 16 months)
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Vejle Hospital
ClinicalTrials.gov Identifier:
NCT01747239
First received: December 6, 2012
Last updated: December 3, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)